Nightmares are among the most distressing symptoms of post-traumatic stress disorder.
For many people living with PTSD, frightening dreams replay traumatic events over and over, causing sudden awakenings, panic and poor sleep. These nightly experiences can make recovery much harder because restful sleep is essential for mental health.
Researchers at Charité–Universitätsmedizin Berlin have reported encouraging results from a study testing a cannabis-based medicine called dronabinol. Dronabinol contains THC, the best-known active ingredient in cannabis. The study was published in Nature Medicine.
THC works by interacting with the body’s endocannabinoid system, which helps regulate mood, sleep and emotional processing. Earlier research suggested it might reduce dream intensity during REM sleep, raising the possibility that it could lessen trauma-related nightmares.
To test this idea, scientists recruited more than 170 people with PTSD who experienced frequent nightmares. Participants took either dronabinol or a placebo before bedtime every night for ten weeks. Because the study was double-blind, neither doctors nor patients knew which treatment each person received during the trial.
The results were encouraging. People receiving dronabinol experienced a much larger reduction in nightmare severity than those taking the placebo. Around one-third became completely free of nightmares, while many others experienced major improvement that allowed them to sleep more comfortably.
Although the medicine helped nightmares, it did not significantly reduce all PTSD symptoms or depression. This suggests that dronabinol targets one particularly troublesome part of the disorder rather than curing PTSD itself. Psychological therapy and other treatments would still remain important.
Safety was also reassuring. The most common side effects included dizziness, headaches and increased appetite, and these were generally mild to moderate. Researchers did not observe serious side effects or signs of dependence after treatment ended.
The researchers believe better sleep may greatly improve quality of life even if other PTSD symptoms continue. Breaking the cycle of repeated traumatic dreams may also make it easier for patients to participate in counselling and other therapies.
This well-designed clinical trial offers some of the strongest evidence so far that a cannabis-derived medicine can reduce PTSD-related nightmares.
Nevertheless, the relatively short treatment period means researchers still need to examine long-term safety, effectiveness and whether tolerance develops. If future studies confirm these results, dronabinol could fill an important gap in PTSD treatment.
Source: Charité – Universitätsmedizin Berlin.
